Sitagliptin

Introduction Overview

Generic Name

sitagliptin

Brand Name

Januvia, Zituvio, Brynovin

Dosage Form

oral tablet

Drug Class

Dipeptidyl peptidase 4 inhibitors

Pharmacokinetics

Absorption:
Sitagliptin is rapidly absorbed following oral administration, with an absolute bioavailability approximating 87%. Peak plasma concentrations (Cmax) are typically reached within 1 to 4 hours post-dose under fasting conditions. Food intake does not significantly affect the rate or extent of sitagliptin absorption, making administration with or without meals clinically acceptable. The consistent oral bioavailability supports once-daily dosing in type 2 diabetes management.

Distribution:
Following absorption, sitagliptin demonstrates a moderate volume of distribution, approximating 198 liters, reflecting distribution beyond the plasma compartment into tissues. Sitagliptin exhibits minimal plasma protein binding (~38%), ensuring a free fraction availability for pharmacologic activity. It does not extensively bind to erythrocytes and shows limited penetration into the central nervous system, consistent with its hydrophilic properties.

Metabolism:
Sitagliptin is minimally metabolized in humans. Approximately 79% of an administered dose is excreted unchanged in urine. The primary metabolic pathway is renal excretion; however, CYP3A4 and CYP2C8 have minor roles in limited oxidative metabolism. Lack of extensive hepatic metabolism reduces the risk of significant drug-drug interactions mediated by cytochrome P450 enzymes.

Elimination:
Renal excretion is the principal route of elimination, with approximately 87% of the administered sitagliptin dose recovered in urine primarily as unchanged drug. The apparent elimination half-life is about 12.4 hours, supporting once-daily dosing. Clearance of sitagliptin decreases in patients with renal impairment, necessitating dose adjustments to avoid accumulation and increased risk of adverse effects. Non-renal clearance constitutes a minor component, and enterohepatic circulation does not significantly affect elimination.

Dosage Forms

Available Dosage Forms:
Sitagliptin is available exclusively as an oral tablet formulation. Multiple dosage strengths are marketed both as the base and as the phosphate salt. The available dosages include:
- Oral tablet (as base): 25 mg, 50 mg, 100 mg
- Oral tablet (as phosphate): 25 mg, 50 mg, 100 mg
These tablets are formulated for once-daily oral administration.

Dosages for Adults and Adolescents:
The recommended standard adult dose for treatment of type 2 diabetes mellitus is 100 mg orally once daily, with or without food. Dose adjustments are recommended in patients with renal impairment:
- Moderate renal impairment (eGFR 30 to <50 mL/min/1.73 m²): 50 mg once daily
- Severe renal impairment or end-stage renal disease requiring dialysis: 25 mg once daily
Dose modifications help mitigate the risk of drug accumulation and hypoglycemia in these populations.

Specific Patient Populations:
In elderly patients, no initial dose adjustment is required; however, renal function assessment is critical for appropriate dosing. Sitagliptin is not indicated in patients with type 1 diabetes or for diabetic ketoacidosis management. Pediatric use is not currently established, and safety and efficacy have not been fully evaluated. Use during pregnancy should follow clinical judgment, balancing hyperglycemia control with potential risks, as data on fetal safety are limited.

Mechanism Of Action

Sitagliptin exerts its antidiabetic effect by selectively inhibiting dipeptidyl peptidase-4 (DPP-4), a serine protease responsible for degrading incretin hormones, primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preventing the rapid inactivation of these incretins, sitagliptin prolongs their physiological activity, thereby enhancing glucose-dependent insulin secretion from pancreatic beta cells.

The increased levels of active GLP-1 and GIP lead to improved insulin release in response to elevated blood glucose, while simultaneously suppressing glucagon secretion from alpha cells during hyperglycemic states. This dual action results in reduced hepatic glucose production and improved glycemic control without increasing the risk of hypoglycemia under normoglycemic conditions.

At the cellular level, sitagliptin's inhibition of DPP-4 prevents cleavage of the N-terminal dipeptide from incretin hormones, stabilizing their active forms. This mechanism differs from other antidiabetic agents such as sulfonylureas or insulin, which directly stimulate insulin release or replace insulin, respectively. Clinical studies demonstrate that sitagliptin yields effective HbA1c reduction, particularly when combined with other agents.

Comparative research reveals sitagliptin has a favorable safety and tolerability profile versus other incretin-based therapies (e.g., GLP-1 receptor agonists), offering the convenience of oral administration with minimal gastrointestinal adverse effects. Emerging evidence suggests potential ancillary benefits on beta-cell preservation and cardiovascular safety, although long-term outcome data continue to evolve.

Pharmacological Actions

Selective inhibition of dipeptidyl peptidase-4 enzyme activity.
Enhancement of endogenous incretin hormone levels (GLP-1 and GIP).
Stimulation of glucose-dependent insulin secretion from pancreatic beta cells.
Suppression of inappropriate glucagon release from pancreatic alpha cells.
Reduction of hepatic glucose output contributing to improved glycemic control.
Improvement of postprandial and fasting blood glucose levels.
Low potential to induce hypoglycemia when used as monotherapy.
Minimal effects on body weight, often weight neutral in clinical use.
Oral bioavailability permitting convenient once-daily dosing.
Limited metabolism reduces interaction risk with cytochrome P450 substrates.
Renal excretion necessitating dose adjustments in renal impairment.
No direct stimulation of insulin release at normoglycemic levels.
Demonstrated efficacy in combination with other antidiabetic agents.
Potential preservation of pancreatic beta-cell function.
Favorable cardiovascular safety profile based on current clinical data.

Therapeutic Or Clinical Uses

Adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus.
Monotherapy in patients inadequately controlled by lifestyle modifications alone.
Combination therapy with other antidiabetic agents such as metformin, sulfonylureas, or insulin.
Management of postprandial hyperglycemia through incretin-mediated insulin secretion.
Used in patients at risk for hypoglycemia requiring agents with low hypoglycemia potential.
Treatment option for patients unable to tolerate other oral hyperglycemics due to safety or tolerability.
Facilitation of HbA1c reduction for long-term glycemic management.
Potential benefit in preserving beta-cell function in early type 2 diabetes.
Option for patients seeking oral therapy with a tolerable side effect profile.
Adjunctive therapy where weight neutrality is desirable.
Management of type 2 diabetes in patients with mild to moderate renal impairment after dose adjustments.
Utilized in combination regimens for comprehensive glucose control in polypharmacy scenarios.
Used in clinical protocols emphasizing safe lowering of blood glucose without inducing hypoglycemia.
May be considered in patients with cardiovascular risk given emerging safety data.
Incorporated in treatment algorithms consistent with contemporary diabetes guidelines.

Side Or Adverse Effects

Upper respiratory tract infection-like symptoms, including stuffy or runny nose, sneezing, and sore throat.
Headache of varying intensity and duration.
Hypoglycemia, particularly when combined with insulin secretagogues or insulin therapy.
Severe joint pain, sometimes disabling, which may require discontinuation.
Pancreatitis presenting with severe abdominal pain radiating to the back, with or without vomiting.
Serious hypersensitivity reactions including anaphylaxis, angioedema, and Stevens-Johnson syndrome.
Severe skin reactions with blistering, peeling, and rash.
Edema and fluid retention associated with heart failure exacerbation.
Renal dysfunction or worsening kidney function in susceptible individuals.
Gastrointestinal symptoms such as nausea or abdominal discomfort (less common).
Possible increased risk of infections due to immunomodulatory effects of incretin elevation.
Fatigue and malaise reported in some patients during therapy initiation.
Allergic skin reactions including rash, pruritus, or urticaria.
Rare reports of severe hypoglycemia when combined with agents that increase insulin secretion.
Potential weight neutrality with minimal weight gain.

Precautions

Monitor for signs and symptoms of pancreatitis; discontinue therapy immediately if suspected.
Use cautiously in patients with a history of pancreatitis or risk factors for pancreatic disease.
Assess renal function prior to initiation and periodically during treatment to determine appropriate dosing.
Exercise caution when co-administered with insulin or sulfonylureas due to increased hypoglycemia risk.
Advise patients to recognize and manage symptoms of hypoglycemia.
Use with caution in patients with heart failure or significant cardiovascular disease due to post-marketing reports.
Screen for hypersensitivity reactions, especially during the initial treatment phase.
Adjust dosage in patients with moderate to severe renal impairment or end-stage renal disease.
Use during pregnancy only if the potential benefit justifies the potential risk; glycemic control during pregnancy is crucial.
Limited data on breastfeeding; advise mothers to consult healthcare professionals for individualized decision-making.
Patients should maintain a consistent manner of administration concerning food intake.
Educate patients about the importance of adherence to diet, exercise, and concomitant diabetes medications.
Caution in patients with a history of alcohol abuse or gallbladder disease, which can influence pancreatitis risk.
Monitor for signs of heart failure in susceptible patients, including edema and dyspnea.
Use with caution in elderly patients due to higher prevalence of renal impairment.

Warnings

Potential risk of severe pancreatitis; immediate discontinuation recommended if symptoms develop.
Serious hypersensitivity reactions, including anaphylaxis, angioedema, and severe skin reactions.
Risk of heart failure exacerbation; monitor for signs such as swelling, rapid weight gain, and shortness of breath.
Risk of severe hypoglycemia, especially when used concomitantly with insulin secretagogues or insulin.
Discontinue therapy warranted in case of severe joint pain or disabling arthritis symptoms.
Use is contraindicated in patients with known hypersensitivity to sitagliptin or any component of the formulation.
Not approved for treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
Patients should be aware of symptoms of low blood sugar and instructed on appropriate management strategies.
Potential interaction with other drugs that influence blood glucose requires careful monitoring and dose adjustment.
Use caution when initiating therapy in patients with renal impairment; dose adjustment necessary to prevent toxicity.
Patients should seek immediate medical attention if signs of allergic or severe skin reactions occur.
Clinicians should regularly monitor renal function and glycemic status during therapy.
Pregnant patients should be managed carefully, with consideration of risks and benefits.
Long-term safety data are continuously being evaluated; current evidence supports cautious clinical use.
Patients should avoid sharing medication and adhere strictly to prescribed indications.

Contraindication

Known hypersensitivity to sitagliptin or any components of the formulation.
Patients with a history of severe hypersensitivity reactions to dipeptidyl peptidase-4 inhibitors.
Use in type 1 diabetes mellitus or for treatment of diabetic ketoacidosis is contraindicated.
Patients with prior documented pancreatitis linked to sitagliptin therapy should avoid use.
Concomitant use with certain medications contraindicated by clinical judgment if significant drug interactions are anticipated.
Patients with severe allergic skin reactions or Stevens-Johnson syndrome attributable to sitagliptin should not receive the drug.
Should not be used as monotherapy in insulin-dependent diabetes.
Contraindicated when any condition exists that would increase risk of severe adverse reactions from incretin-based therapies.
Patients with hypersensitivity to phosphate salts may require caution or avoidance of phosphate salt formulations.
Contraindicated in situations where oral administration is not feasible due to malabsorption or gastrointestinal disease.
Avoid use in breastfeeding mothers unless benefits outweigh risks and alternate therapies are unsuitable.
Not recommended during pregnancy unless benefit justifies potential fetal risk.
Any documented intolerance or allergy to related DPP-4 inhibitors precludes use.
Use is not permitted in pediatric patients as safety and efficacy have not been established.
Avoid in patients exhibiting severe renal impairment without appropriate dose adjustment and monitoring.

Drug Interactions

Concomitant use with insulin secretagogues (e.g., sulfonylureas) or insulin may increase risk of hypoglycemia; dose adjustment may be necessary.
Minimal metabolism by cytochrome P450 enzymes reduces risk of interactions with CYP3A4 or CYP2C8 substrates or inhibitors.
Drugs affecting renal function or renal clearance (e.g., diuretics, NSAIDs) may alter sitagliptin elimination; renal monitoring advised.
Coadministration with P-glycoprotein inhibitors (e.g., ketoconazole) may increase sitagliptin plasma concentrations, warranting caution.
Simultaneous use with medications impacting blood glucose levels (e.g., corticosteroids, beta-blockers) can complicate glycemic control.
Concurrent use with digoxin has not demonstrated clinically significant interactions but monitoring is prudent due to narrow therapeutic index of digoxin.
Interference with oral contraceptives is unlikely, but clinical evaluation should be considered for women of childbearing potential.
Combination with other incretin-based therapies is generally avoided to prevent additive adverse effects.
Herbal supplements with hypoglycemic effects (e.g., ginseng, fenugreek) may potentiate hypoglycemic risk when used with sitagliptin.
Alcohol intake may exacerbate hypoglycemia or adverse effects; patient counseling recommended.
Co-administration with immunosuppressive agents requires close clinical surveillance due to potential immune modulation.
Drugs altering gastrointestinal motility could theoretically affect sitagliptin absorption; clinical relevance is limited.
No significant interactions reported with commonly used antihypertensives or lipid-lowering agents.
Adjustment of concomitant medications influencing blood sugar is critical upon initiation or discontinuation of sitagliptin.
Patients should inform providers about all prescription, OTC, and herbal products to avoid unintended interactions.

Preparations Of The Drug

Oral tablets as sitagliptin phosphate monohydrate and sitagliptin base in strengths of 25 mg, 50 mg, and 100 mg.
Packaged for oral administration once daily, with or without food.
Available branded formulations include Januvia, Zituvio, and Brynovin.
Manufactured and supplied in standard tablet blister packs or bottles with specific storage instructions.
Tablets contain inactive ingredients (excipients) facilitating stability and absorption.
Certain brands require storage in original containers and use within three months after opening to maintain potency.
Prescribed solely for treatment of type 2 diabetes mellitus as adjunctive therapy.
Preparation storage guidelines include room temperature away from moisture and heat.
No injectable or alternative delivery forms currently approved or marketed.
Produced under Good Manufacturing Practices ensuring quality and consistency.
Pharmaceutical formulations designed to optimize bioavailability and patient compliance.
Tablets are film-coated to facilitate swallowing and mask taste.
Contains no significant allergens; however, excipients may vary by manufacturer.
Commercially available through prescription pharmacies worldwide.
Accompanied by comprehensive patient information leaflets detailing indications, dosing, and precautions.